Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Connecticut's Blumenthal questions Smart Choices

This article was originally published in The Tan Sheet

Executive Summary

Connecticut Attorney General Richard Blumenthal follows other government officials in raising concern about the food industry's Smart Choices, a voluntary nutrition labeling program. Blumenthal wrote letters to food firms that participate in the program, such as Kellogg Co. and General Mills, expressing his concern and requesting information on the development of the program. Executives from the Smart Choices program say they will work with Blumenthal, according to media reports. Rep. Rosa DeLauro, D-Conn., wrote a letter to FDA in September, asking the agency to investigate whether Smart Choices allows firms to misrepresent unhealthy food as healthy (1"The Tan Sheet" Sept. 28, 2009). FDA and the Department of Agriculture are also inquiring about the program

You may also be interested in...



DeLauro Urges FDA To Probe Whether Smart Choices Really Are

Rep. Rosa DeLauro is pushing FDA to investigate whether the food industry's Smart Choices voluntary front-of-package nutrition labeling program allows companies to misrepresent unhealthy food choices as healthy

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Topics

UsernamePublicRestriction

Register

PS103430

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel